Roche-Ionis sefaxersen kidney-drug approval path

Mapped to your portfolio

Overview

Description Roche and Ionis are advancing sefaxersen toward potential regulatory review after positive interim Phase 3 kidney-disease results. Overview Sefaxersen met the primary goal in an interim Phase 3 study of patients with IgA nephropathy. The companies reported a statistically significant and clinically meaningful reduction…

Possible scenarios

45%Favorable Regulatory Path+0.0%
25%Competitive Market Outcome+0.0%
20%Data Caveats Delay-0.0%

For information only. Not investment advice.

Stories in this saga

1 story, 1 source

Sep 23, 2026
Roche and Ionis Hit Primary Phase 3 Goal for Kidney Drug

Roche-Ionis sefaxersen kidney-drug approval path

Mapped to your portfolio

Overview

Possible scenarios

Stories in this saga

Roche and Ionis Hit Primary Phase 3 Goal for Kidney Drug

Portfolio

Portfolio

Possible scenarios

Mapped to your portfolio

Mapped to your portfolio

Overview

Possible scenarios

Keeping an eye on this saga?

Stories in this saga

Roche and Ionis Hit Primary Phase 3 Goal for Kidney Drug

Portfolio

Portfolio

Possible scenarios

Mapped to your portfolio